KAYAK2U

December 11, 2011

Hemorrhaging brains

Dr. Kate Scannell, plainly out of her league, laments:

It's stunning that we would need to invent a law to discourage entrepreneurs from taking such financial advantage of sick people during a national prescription drug shortage. You would hope that no self-respecting pharmaceutical distributor would want to be seen in such a sickening light.

Yet here we are again, trying next week to propose a new law to reinforce what ought to be obvious common morality. Here we are again, spending valuable taxpayer time and money on legislative efforts to reprimand egregiously bad behavior within the U.S. pharmaceutical market.

Our national prescription drug shortage — which sets the dark stage for such successful price-gouging — has been worsening for years in front of our politicians' blind eyes. The number of reported drug shortages each year has more than quadrupled recently — from 61 in 2005, to more than 250 within the current year (so far).

You have to wonder why so little is being done to solve this national health care crisis. Appeals to patient care and safety don't seem to be motivating drugmakers and distributors to do the right thing.

The "new law" to which she refers is one of Chucky Schumer's more idiotic endeavors (Yes, it's that bad).  I have a draft blog on that thing, which I'll probably never finish, for what that's worth.  (My earlier comments on Schumer's endeavor, here.)

To answer Scannell, the people jacking up prices in the face of the current shortages are doing the moral thing.  They are preserving and conserving their supply of drugs.  Were they NOT to jack up their prices, their supply would soon be gone like everyone else's, and then there would be no such drugs at any price.  I ask Scannell:  Which would you prefer, drugs at a market price, however unfair you deem that price to be, or no drugs at all?

Further, whoever acquires said drugs, like the afore mentioned middlemen do, can do anything they want with them, including not selling them at any price.  Should Scannell decide to go into the drug distribution business, she might very well choose to sell them below her own cost, but she might also come to realize that doing so is not a sustainable business model, just as it might occur to her (at some point) that hoarding drugs and hoping to sell them at prices no one is willing to pay is also not a sustainable business model.

Scannell's misunderstanding of things goes deeper:

One might reasonably ask: Well, why not just manufacture more drugs to meet the demands of this crisis, and increase the supply to drive down costs? Indeed, aren't drug companies generally happy to make and sell their products?

It isn't the drug manufactuers who are enjoying the difference between low manufacturing cost and high prices.  It's middlemen.  The drug companies are restricted in several ways (price controls, and quotas, to name two), BY THE GOVERNMENT, from reaping the rewards of doing more business.

Also, it's nonsense to suppose that a company should endeavor to "increase the supply to drive down costs".  Scannell is either using the wrong word ("costs") or misunderstanding the driver of economies of scale.  In mature products, such as those under consideration, costs are pretty much fixed (though that is another problem Scannell doesn't factor in:  Costs for components have been rising), so one suspects that Scannell is conflating "cost" and "price", and still being wrong absent the conflation.

All companies have finite resources.  In business terms, it makes no sense for a company to expand production of one line (generic drugs with price contols and quotas) that contributes very little to their bottom line and continued existence, versus promoting those lines that further their continued existence (other drugs that earn the money that sustains the business).

Relatedly, here's another insight from another story I haven't managed to blog:  Congress holds hearing on national drug shortage:

Hudspeth and others who plan to testify tomorrow said they believe the shortage is linked to the 2003 Medicare Modernization Act that was supposed to create more transparency in pricing. But it also resulted in the changing of the reimbursement rate for drugs from a percentage of average wholesale price to average selling price, including all discounts. The current model makes it difficult for drug companies to raise prices more than 6 percent a year.

It's good to see someone who has a clue, but I have seen exactly zero reports out of those hearings that were allegedly held at the end of November, though I haven't explicitly searched for them.

What we have, then, is a market that's been thrown out of whack by government interference (ie., the 2003 Medicare Modernization Act  and a plethora of other regulations), with middlemen taking advantage of the situation, as middlemen will do, with the government and useful idiots like Scannel now blaming the middlemen for capitalizing on a situation the government created.

I suppose it would be impolite to ask Dr. Scannell if she is a recipient of government funds in her day to day practice.

In any event, it's difficult to tell whether Scannell is just someone who hasn't thought through the things she's written, or whether she's written the things she has in order to perpetuate certain ignorances among the general population.

I would suggest to Dr. Scannell that companies don't often choose not to make money in areas where there is money to be made.  If companies are shying away from endeavors that Dr. Scannell thinks obvious money makers, perhaps Dr. Scannell should re-evaluate her assumptions in said regards.

[Edited for typos, readability, and other non-nefarious reasons.]

MikeSoja - December 11, 2011 -- 01:48 am    Filed in: Health care, Shortages  
« It’s a gas, gas, gas…
Factoid »
As Happy As A Clam

Kayak2U.com

msoja RSS 2.0

Other's Pages









Search

Archive

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  


  • Books4Sale



    Soja's GoodReads Books4Sale Cheap

  • Category Cloud


  • Tag Cloud